^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Drug:Rituxan (rituximab) (CD20 inhibitor) +
bortezomib (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Mantle cell lymphoma: Preferred regimens...bortezomib+/-rituximab